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Research into antibodies
essentially began in the 1890s
with the discovery of serum
therapy by Behring and Kitasato.
Serum from one individual who
was recovering from a bacterial
infection could be used to protect
another from the effects of the
bacterial toxins. From this very
beginning there was a twin focus
to research into antibodies —
the structural basis of their 
diverse specificities and their 
exploitation for use in therapy.
César Milstein, who died on 24
March, spent the major part of his
research career working on
antibodies, making outstanding
contributions to both areas.
Behring’s discovery was
recognised by the award in 1901
of the first Nobel Prize in
Physiology or Medicine. Milstein
and Köhler’s discovery of
monoclonal antibodies was
recognised in the 1984 award.
The immune system has
provided a fertile meeting ground
for scientists trained in a wide
variety of disciplines. Milstein’s
training was firmly rooted in
biochemistry. His first research
degree (a doctorate in chemistry)
was obtained at the University of
Buenos Aires working on yeast
aldehyde dehydrogenase. In 1958,
he won a British Council
Scholarship to come to
Cambridge to work in the
department of biochemistry with
Malcolm Dixon, a leading
enzymologist. As befitted a British
Council Scholar at the time,
Milstein was paid to travel first
class. However, his wife Celia
(whom he had met at student
political meetings in Buenos Aires)
was not similarly treated and had
to tag along in a third class cabin.
Despite this inauspicious start, the
Milsteins maintained a devoted
partnership that lasted till César’s
death with the two occasionally
collaborating on aspects of
immunoglobulin biochemistry.
Milstein’s PhD with Dixon (his
second doctorate) was on the
activation of the enzyme
phosphoglucomutase by heavy
metals. The Cambridge
biochemistry department was an
exciting place to be. So much so
indeed that champagne-induced
inattention on the afternoon
following the announcement of
Fred Sanger’s Nobel Prize caused
Milstein to lose his first, precious
crystals of phosphoglucomutase
into the ice-bath.
Milstein himself put much
effort into improvements in
the technology as well as
exploring the range of its
utility. These projects
involved interactions with
many other collaborators,
usually becoming friends,
and friends often becoming
collaborators
However, Sanger influenced
Milstein’s career in many other —
much more beneficial — ways.
They collaborated on defining the
amino acid sequence around the
active site of the enzyme and
Sanger made clear to Milstein that
he would be welcome to return to
Cambridge if things did not work
out following Milstein’s impending
returning to Argentina. This was
an offer which Milstein took up
some two years later.
The political turbulence and
interference by the military
government made it impossible
for Milstein to continue his work in
his old institute in Buenos Aires. In
1963 he returned to Cambridge to
work in the division of protein
chemistry which Sanger then
headed in the newly formed
Medical Research Council
Laboratory of Molecular Biology.
Although Milstein was never to
work again in Argentina, he
maintained close contact with
Argentinian science and scientists
throughout his life. On his return
to Cambridge, Milstein shifted the
focus of his research from
enzymes to antibodies. This is a
shift that he attributed to the
influence of Sanger, who had
previously had a graduate student
(Rodney Porter) working in the
same area.
During the 1960s, Milstein
worked extensively on the
structure of antibody molecules —
investigating the arrangement of
their disulphide bridges and the
nature of their sequence diversity.
The genetic basis of antibody
diversity was a topic that also
interested Sydney Brenner and
Francis Crick in the Molecular
Genetics division at the MRC Lab.
Indeed, Brenner and Milstein co-
authored an influential but
experiment-free letter to Nature
proposing that antibody diversity
could be attributable to error-
prone DNA synthesis — a
proposal that has resurfaced as a
possible explanation of antibody
affinity maturation (rather than the
generation of the primary antibody
repertoire).
Several models were circulating
during that period to explain the
diversity that was evident from
immunoglobulin polypeptide
sequences. Many of the workers
in the field came together for the
1967 Cold Spring Harbor
symposium on Antibodies. This
symposium was famously
summarised by Niels Jerne in a
chapter entitled ‘Waiting for the
End’. In fact, from the perspective
of those of us who entered the
antibody field after the 1976
discovery of immunoglobulin 
gene rearrangement, 1967 looks
Obituary
César Milstein (1927–2002)
Michael Neuberger looks back at the life of one of the creators of
monoclonal antibodies that won him a share of the 1984 Nobel prize,
and opened up new fields for both diagnostic and therapeutic uses of
the antibodies. 
rather more like the end of the 
beginning than the beginning of
the end.
During subsequent years, work
on antibody diversity shifted — in a
conventional counter-dogma
fashion — from polypeptide
through to RNA back to DNA.
In vitro translation of the mRNA
encoding immunoglobulins
enabled Milstein, Brownlee and
collaborators to obtain the first
evidence of an amino-terminal
leader sequence that could act as
a signal for secretory polypeptides.
Hybridisation experiments, in
collaboration with Rabbitts,
permitted the counting of
immunoglobulin gene sequences.
Much of this work was enabled by
the availability of mouse myeloma
cell lines that could be grown in
culture. It was in the hope of
getting insight into the genetics of
antibody production (and the 
basis of the allelic exclusion) 
that in 1973 Cotton and Milstein
investigated what the effects
would be on immunoglobulin
production if two immunoglobulin-
producing myeloma cells were
fused together. This provided the
prelude to the landmark 1975
paper by Köhler and Milstein in
which hybridomas were
established by fusion of splenic
B cells from immunised mice with
the mouse myeloma line.
The monoclonal antibody
technology was rapidly taken up
by the scientific community,
allowing the purification,
identification and tracing of a vast
variety of ligands. Milstein himself
put much effort into
improvements in the technology
as well as exploring the range of
its utility. These projects involved
interactions with many other
collaborators, usually becoming
friends, and friends often
becoming collaborators. He was
particularly enthusiastic about the
exploitation of monoclonals as
cell lineage markers and was an
active participant in workshops
devoted to lymphocyte
differentiation markers. Indeed,
the first antigen defined by such
workshops — CD1 — became a
continued focus of research for
Milstein, undeterred by the fact
that nothing was known at the
time about its biological function.
Whereas the exploitation of
monoclonals for use in
diagnostics was rapid (where they
have reached the domestic
market as components of home
pregnancy testing kits), their
widespread use in therapy has
taken longer to materialise —
awaiting the development of
methods allowing the production
of human or humanised
monoclonal antibodies.
Milstein himself was one of the
first to spot the benefit that might
be reaped by exploiting
recombinant DNA technology for
the production of engineered
antibodies. In his last few years,
Milstein was able to see a rapid
expansion in the use of
monoclonals in therapy — for
example, in the treatment of
breast cancer, lymphoma and
rheumatoid arthritis as well as in
the prevention of infection in
premature infants. Many other
applications are in the pipeline.
Much has been written about
the failure to patent monoclonal
antibodies. Milstein was keen to
protect intellectual property, as
well as the interests of the
Medical Research Council, in the
many areas in which he made
discoveries. He did, however,
point out that whereas the
purpose of patents was to protect
intellectual property and thereby
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At home in the lab: As the last appoint-
ment in his career, Milstein listed ‘retired
(active) worker’, an enviable situation in
which he was able to pursue his interests
without administrative responsibilities.
(Photograph MRC).
permit publication of information
allowing the furtherance of the
research enterprise, there was
nevertheless good reason to
believe that the rapid exploitation
of monoclonal antibodies had
been facilitated by the very fact
that they were not patented.
The success of monoclonal
antibodies did not cause Milstein
to neglect his original interest in
antibody diversity. Some of the
work on antibody production by
myeloma cells was performed in
the hope that these cells would
exhibit ongoing antibody
diversification and therefore
permit analysis of the
diversification process — a line of
approach that was in many ways
ahead of its time.
Furthermore, the hybridoma
technology itself allowed him to
further his original interests. By
establishing hybridomas at
different stages of an immune
response, Milstein and colleagues
were able to chart the mutations
that accumulate in the
immunoglobulin V gene during the
course of the response thereby
providing a detailed description of
antibody affinity maturation.
As the last appointment in his
career, Milstein listed ‘retired
(active) worker’ — an enviable
situation in which he was (with the
assistance of a small group) able
to pursue his research interests
without administrative
responsibilities. And active he
remained until the end.
He was developing new
diagnostic applications of
monoclonal antibodies, was
scheduled to examine a PhD
dissertation on CD1 and had,
within a week of his death,
contributed a manuscript for
publication on antibody
diversification. He certainly
followed the advice that I had been
given when young — ‘Leave the
party while you are still enjoying it’.
The party will obviously continue,
greatly saddened by his absence,
but with its activities and
participants inspired by his
multitude of contributions.
Michael Neuberger is at the Medical
Research Council Laboratory of
Molecular Biology, Hills Road,
Cambridge CB2 2QH, UK.
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Quick Guide
BDNF
A. Kimberley McAllister
What is it? Brain-derived
neurotrophic factor (BDNF) is a
member of the neurotrophin family
of growth factors. It is a basic,
homodimeric, secretory protein
with a molecular mass of ~27 kDa.
Are there related proteins? Yes.
There are three other members of
the neurotrophin family found in
mammals, including nerve growth
factor (NGF), neurotrophin-3
(NT-3) and neurotrophin-4
(NT-4/5). Neurotrophins are similar
in structure and sequence and are
likely derived from a common
ancestral gene. NT-6 and -7 have
been recently found only in fish.
Where is it found? BDNF is
located in specific neuronal
populations at low levels in the
peripheral nervous system (PNS)
and at much higher levels in the
central nervous system (CNS). It is
most highly expressed in the
developing brain, but is still
expressed at lower levels in the
adult brain. Moreover, expression
of BDNF is rapidly and potently
regulated by synaptic activity.
How does BDNF work? BDNF
acts through binding to two
receptors: TrkB and p75. Binding
to the high affinity tyrosine kinase
receptor, TrkB, mediates most of
the neuronal effects of BDNF.
However, BDNF can also bind to a
pan-neurotrophin receptor, p75, to
influence cell death and, perhaps,
to modulate the effects of the
other neurotrophins. BDNF
binding to TrkB induces receptor
dimerization, phosphorylation, and
activation of the intracellular
tyrosine kinase domain. These
events initiate several complex
intracellular signal transduction
cascades.
What is the function of BDNF?
As a classic neurotrophin, BDNF
is believed to be produced in
limited amounts within
postsynaptic neurons where it
serves to match the size of
afferent neuronal populations with
their targets during development.
This traditional view of
neurotrophin function is called the
‘Neurotrophin Hypothesis.’
Are there additional roles for
BDNF? Yes! BDNF influences
almost all aspects of nervous
system development including
neuronal proliferation, neuronal
migration, axon pathfinding,
dendritic growth, synapse
formation and maintenance,
synaptic competition and pruning,
neuronal excitability, both
inhibitory and excitatory synaptic
transmission, long-term plasticity,
and neuronal survival. Perhaps
most exciting, BDNF has been
implicated in mediating the effects
of synaptic activity on neuronal
morphology and connectivity in
the developing brain. Although
BDNF plays many roles in the
developing and adult brain, it
affects only those neurons that
express TrkB or p75.
Can we live without it? No,
although NT-4 can partially
compensate for a lack of BDNF.
BDNF–/– mice show severe
neuronal deficits and early
postnatal death.
Is there anything we don’t know
about BDNF? Yes, a lot. Although
BDNF is implicated in many
aspects of brain development, the
intracellular mechanisms of BDNF
action remain largely unknown.
And it is unclear where and how
BDNF is secreted from neurons.
Finally, the function of BDNF in the
adult brain is almost completely
unexplored.
Where can I find out more?
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